Clinical trials
Kidney Transplant Rejection clinical trials
Below are recruiting kidney transplant rejection clinical trials, each written for real people, not researchers. We’re tracking 80 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06698614Recruiting
Magnetic resonance imaging to study kidney disease
This study uses a special MRI scan to look at the kidneys in people with different kinds of kidney disease, including acute kidney injury, chronic kidney disease, vasculitis, and after a kidney transplant. The goal is to better understand these conditions.
EdinburghAges 18 years+ - NCT06751602Enrolling by invitationPhase 2
Belumosudil to prevent kidney scarring after transplant
This trial tests whether a drug called belumosudil can reduce scarring in the kidney after transplant. Scarring can lead to kidney damage over time, and this study aims to stop that from happening.
Houston, TexasAges 18–75 - NCT07275632RecruitingPhase 1/Phase 2
Testing vonoprazan to prevent delayed kidney function after transplant
This trial tests whether a medicine called vonoprazan fumarate can help prevent delayed kidney function after a first kidney transplant from a deceased donor. It is for people who are ready to follow standard post-transplant care.
ChongqingAges 18 years+ - NCT06493526RecruitingPhase 4
Mycophenolate therapy for kidney transplant patients with no DQ mismatch
This trial tests a mycophenolate-based therapy for kidney transplant recipients who have no HLA-DQ mismatch. If you had your first kidney transplant 3-12 months ago without DQ mismatch and are on standard immunosuppressants, you may qualify.
Edegem, AntwerpAges 18 years+ - NCT04526431Recruiting
Tacrolimus dose study in early kidney transplant patients
This study looks at how tacrolimus (a rejection-preventing medicine) should be dosed in the first days to years after a kidney transplant. It may help personalize dosing by comparing different patient groups, including using genetic testing.
Grenoble, Auvergne-Rhône-AlpesAges 18 years+ - NCT05900401RecruitingPhase 1/Phase 2
Immune tolerance study for kidney transplant recipients
This study tests whether giving a special mix of donor immune cells along with immune-suppressing medicines right after a kidney transplant can help the body accept the new kidney without long-term anti-rejection drugs. It aims to reduce the need for daily transplant medications.
Boston, MassachusettsAges 18–65 - NCT05508009RecruitingPhase 1/Phase 2
Kidney transplant with donor-matched stem cell treatment
This early-phase trial tests a stem cell transplant from a donor who is an extremely close match, given to people who are about to receive a kidney transplant from the same donor. The goal is to improve how well the new kidney works by resetting the immune system to better accept the transplant.
Palo Alto, CaliforniaAges 1–30 - NCT05385432RecruitingPhase 3
Kidney transplant induction therapy for sensitized patients
This trial tests a specific “induction” treatment to help people who have stronger immune reactions from past sensitizing events during a kidney transplant. It may help improve how well the transplant works and how safely the immune system is managed.
ToursAges 18–79 - NCT01644903Recruiting
Checking biomarkers after a liver transplant
This study follows people who are getting a liver transplant (including repeat transplants) to monitor changes in their body using test results. It may help doctors understand how patients are doing after transplant and improve care over time.
Chicago, IllinoisAges 18 years+ - NCT06752577Recruiting
Stem cell treatment for chronic kidney disease safety study
This study tests whether a single infusion of stem cells from bone marrow is safe for people with chronic kidney disease (CKD). It aims to see if this treatment can help slow kidney function loss.
Jacksonville, FloridaAges 18 years+ - NCT07141043Recruiting
Bone health study after kidney transplant
This study looks at bone and mineral disorders in people on dialysis, after a kidney transplant, or with bone thinning. It aims to understand how these conditions affect bone health.
IașiAges 20–70 - NCT07053488RecruitingPhase 1/Phase 2
Gene-edited liver transplant to lower rejection risk
This trial tests a liver transplant using a donor organ that has been gene-edited to reduce the risk of rejection. It may help people who need a liver transplant and are not a perfect tissue match with their donor.
Beijing, ChangpingAges 16–85 - NCT07532382Recruiting
Personalized Stories to Help Young Kidney Transplant Recipients
This study uses personalized storytelling to help children aged 5–12 who have received a kidney transplant. Researchers believe that hearing stories from other transplant recipients might help children understand their condition better and cope with their new life after transplant.
Paris, Île-de-France RegionAges 5–12 - NCT06263426Recruiting
Kidney transplant from donors with HIV: impact on rejection and long-term results
This study tests whether kidney transplants from donors with HIV are safe and effective for people with HIV who need a new kidney. It looks at long-term outcomes like rejection and survival.
Birmingham, AlabamaAges 18 years+ - NCT07444489Enrolling by invitationPhase 3
Long-term safety of felzartamab for kidney transplant rejection
This study checks the long-term safety of felzartamab for people who have had a kidney transplant and are dealing with antibody-mediated rejection or signs of inflammation in the kidney. It's for those who were already in a previous study and took at least one dose of felzartamab.
Los Angeles, CaliforniaAges 18–75 - NCT03591302RecruitingPhase 1
Stem cell transplant to stop anti-rejection drugs after kidney transplant
This study tries to use a stem cell transplant from your original kidney donor to help your body accept the kidney without needing lifelong anti-rejection drugs. You must have a perfectly matched sibling donor who is still available.
Palo Alto, CaliforniaAges 18 years+ - NCT06406179Recruiting
Blood test for donor DNA in kidney transplant care
This trial is testing whether a simple blood test that looks for donor DNA can help doctors take better care of kidney transplant patients. It may help detect early signs of rejection and guide treatment decisions.
ParisAges 18 years+ - NCT07090512Recruiting
Ultrasound to predict kidney risk after transplant
This study uses ultrasound of donor kidneys to predict the risk of kidney problems after transplant. It may help doctors better understand transplant outcomes.
Jinan, ShandongAges 18 years+ - NCT01957696Enrolling by invitation
Study of pancreas (and sometimes kidney) transplant outcomes
This study looks at people who receive a pancreas transplant, with or without a same-time kidney transplant, and follows them to understand their results. It may help improve how transplant teams choose patients and manage care after surgery.
OsloAges 18–65 - NCT06568549RecruitingPhase 4
Reducing Immunosuppression in Older Kidney Transplant Patients (RIOT Trial)
This trial tests whether older kidney transplant recipients can safely reduce their immunosuppression medications using a special monitoring tool called Trugraf. If you are over 55, have had a stable transplant, and want to possibly lower your medications, this study may be for you.
Phoenix, ArizonaAges 55 years+ - NCT07423247RecruitingPhase 4
Tirzepatide for weight loss in kidney transplant patients
This trial tests if tirzepatide can help people who have had a kidney transplant and are still overweight lose weight. It may be an option if you have had your transplant at least a year ago, your kidney function is stable, and your body mass index is 27 or higher.
TehranAges 18 years+ - NCT07219043RecruitingPhase 2
Felzartamab for kidney transplant patients with inflammation
This trial tests a drug called felzartamab to see if it can help people who have a type of kidney inflammation after a transplant, even without donor-specific antibodies. It might offer a new treatment option for those who are not getting better on their own.
Loma Linda, CaliforniaAges 18–74 - NCT07024238Enrolling by invitation
Short-chain fatty acid supplement for kidney transplant patients
This study tests whether taking a short-chain fatty acid (a type of fiber-like substance) supplement can improve gut health in people who have had a kidney transplant. It may help keep the transplant working well.
Martin, SlovakiaAges 18 years+ - NCT06552169RecruitingPhase 2
Treg cell therapy to lower anti-rejection meds after kidney transplant
This trial tests whether adding a special type of immune cell (Treg cells) to standard therapy can help kidney transplant recipients safely take lower doses of anti-rejection medicines. It is for people who are getting a kidney from a living donor.
Phoenix, ArizonaAges 18–65
Hear when a new Kidney Transplant Rejection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for kidney transplant rejection?
- Yes. Clin2 currently lists 80 recruiting kidney transplant rejection studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a kidney transplant rejection trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a kidney transplant rejection trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.